glp-1 drops Novo Nordisk Announces Significant Price for Popular Medications EllieMD | GLP-1 Oral Drops
Description
Our findings strongly suggest the answer is yes. Primes recent real-world study found 63% of high-potency GLP-1 (Wegovy or Zepbound) users who started treatment in Q1 2024 are still taking their medication after a year
Should Medicare and Medicaid expand to cover weight loss drugs
A new case report highlights the potential risk of "anhedonia" from high doses of tirzepatide, though it can be treated effectively.
Why the hype: Diabetes, obesity, and vascular disease are known contributors to brain aging and dementia risk
Ozempic, Wegovy, Mounjaro, Zepbound what's the difference
The positive impact of GLP-1RA therapy on lipids is an important contributor to these outcomes.
